Estimating the impact of enhanced care at minority‐serving hospitals on disparities in the treatment of breast, prostate, lung, and colon cancers

Abstract

AbstractBackgroundThe objective of this study was to quantify disparities in cancer treatment delivery between minority‐serving hospitals (MSHs) and non‐MSHs for breast, prostate, nonsmall cell lung, and colon cancers from 2010 to 2019 and to estimate the impact of improving care at MSHs on national disparities.MethodsData from the National Cancer Database (2010–2019) identified patients who were eligible for definitive treatments for the specified cancers. Hospitals in the top decile by minority patient proportion were classified as MSHs. Multivariable logistic regression adjusted for patient and hospital characteristics compared the odds of receiving definitive treatment at MSHs versus non‐MSHs. A simulation was used to estimate the increase in patients receiving definitive treatment if MSH care matched the levels of non‐MSH care.ResultsOf 2,927,191 patients from 1330 hospitals, 9.3% were treated at MSHs. MSHs had significant lower odds of delivering definitive therapy across all cancer types (adjusted odds ratio: breast cancer, 0.83; prostate cancer, 0.69; nonsmall cell lung cancer, 0.73; colon cancer, 0.81). No site of care–race interaction was significant for any of the cancers (p > .05). Equalizing treatment rates at MSHs could result in 5719 additional patients receiving definitive treatment over 10 years.ConclusionsThe current findings underscore systemic disparities in definitive cancer treatment delivery between MSHs and non‐MSHs for breast, prostate, nonsmall cell lung, and colon cancers. Although targeted improvements at MSHs represent a critical step toward equity, this study highlights the need for integrated, system‐wide efforts to address the multifaceted nature of racial and ethnic health disparities. Enhancing care at MSHs could serve as a pivotal strategy in a broader initiative to achieve health care equity for all.